Comparing Bullfrog AI (NASDAQ:BFRG) & iSpecimen (NASDAQ:ISPC)

Bullfrog AI (NASDAQ:BFRG) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Bullfrog AI and iSpecimen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	1	0	0	1.50
iSpecimen	1	0	0	0	1.00

Institutional and Insider Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by company insiders. Comparatively, 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Bullfrog AI and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-150.36%	-127.98%
iSpecimen	-2,445.40%	-524.39%	-140.42%

Volatility and Risk

Bullfrog AI has a beta of -2.73, indicating that its stock price is 373% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bullfrog AI and iSpecimen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120,000.00	109.48	-$6.50 million	($0.46)	-1.54
iSpecimen	$1.93 million	1.44	-$10.49 million	($56.44)	-0.02

Bullfrog AI has higher earnings, but lower revenue than iSpecimen. Bullfrog AI is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Summary

Bullfrog AI beats iSpecimen on 8 of the 12 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.